Review of choice and use of antidepressants

Progress in Neurology and Psychiatry

Volumn 13, Issue 1, 2009, Pages 14-20

  Bleakley, Stephen ^a  

^a Hampshire Partnership Trust   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

AGOMELATINE; AMFEBUTAMONE; AMINE OXIDASE (FLAVIN CONTAINING); AMITRIPTYLINE; ANTIDEPRESSANT AGENT; CITALOPRAM; CLOMIPRAMINE; DOSULEPIN; DULOXETINE; ESCITALOPRAM; FLUOXETINE; FLUVOXAMINE; IMIPRAMINE; ISOCARBOXAZID; LITHIUM SALT; LOFEPRAMINE; MIRTAZAPINE; MOCLOBEMIDE; MONOAMINE OXIDASE INHIBITOR; NORTRIPTYLINE; OLANZAPINE; PAROXETINE; PHENELZINE; PLACEBO; SEROTONIN UPTAKE INHIBITOR; SERTRALINE; TRANYLCYPROMINE; TRICYCLIC ANTIDEPRESSANT AGENT; UNINDEXED DRUG; VENLAFAXINE;

ANTICHOLINERGIC SYNDROME; BREAST FEEDING; DEPRESSION; DIZZINESS; DOSE RESPONSE; DRUG CHOICE; DRUG CONTRAINDICATION; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG HALF LIFE; DRUG MEGADOSE; DRUG SAFETY; DRUG TREATMENT FAILURE; DRUG WITHDRAWAL; ELECTRIC SHOCK; ELECTROCONVULSIVE THERAPY; FLU LIKE SYNDROME; HUMAN; HYPONATREMIA; NAUSEA; PHARMACOLOGICAL BLOCKING; PREGNANCY; PRENATAL DRUG EXPOSURE; PRIORITY JOURNAL; REMISSION; REVIEW; RISK FACTOR; SEDATION; SEROTONIN SYNDROME; SEXUAL DYSFUNCTION; SIDE EFFECT; SUICIDAL BEHAVIOR; TREATMENT DURATION; TREATMENT RESPONSE; VOMITING;

EID: 63249085790     PISSN: 13677543     EISSN: None     Source Type: Journal    
DOI: 10.1002/pnp.107     Document Type: Review

References (34)

1. World Health Organization. Mental Health. Depression http://www.who.int/ en/
2. Keller MB, Lavori PW, Rice J, et al. The persistent risk of chronicity in recurrent episodes of nonbipolar major depressive disorder: a prospective follow-up. Am J Psychiatry 1986;143:24-8.
3. Mueller T, Leon A, Keller M, et al. Recurrence after recovery from major depressive disorder during 15 years of observational follow up. Am J Psychiatry 1999;156:1000-6.
4. Anderson IM, Ferrier IN, Baldwin RC, et al. Evidence-based guidelines for treating depressive disorders with antidepressants: A revision of the 2000 British Association for Psychopharmacology guidelines. J Psychopharm 2008:22;343-96.
5. National Institute for Health and Clinical Excellence. Depression (amended). Management of depression in primary and secondary care. Clinical guideline 23. www.nice.org.uk. 2004
6. Posternak MA, Miller I. Untreated short-term course of major depression: a metaanalysis of outcomes from studies using wait-list control groups. J Affect Disord 2001:66;139-46.
7. Walsh T, Seidman S, Sysko R, et al. Placebo response in studies of major depression variable, substantial and growing. JAMA 2001:287;1840-7.
8. Khan A, Brodhead AE, Schwartz KA, et al. Severity of depressive symptoms and response to antidepressants and placebo in antidepressant trials. J Psychiatr Res 2005:39;145-50.
9. Kirsch I, Deacon B, Huedo-Medina T, et al. Initial Severity and antidepressant benefits: A meta-analysis of data submitted to the food and drug administration. 5:e45 www.plosmedicine.org 2008
10. Geddes J, Carner S, Davies C, et al. Relapse prevention with antidepressant drug treatment in depressive disorders: a systematic review. Lancet 2003;361:653-61.
11. Nemeroff C, Entsuah R, Benattia I, et al. Compare analysis of remission (COMPARE) with venlafaxine versus SSRIs. Biol Psychiatry 2008;63:424-34.
12. Kennedy S,Anderson H, Lam R. Efficacy of escitalopram in the treatment of major depressive disorders compared with conventional selective serotonin reuptake inhibitors and venlafaxine XR: a meta analysis. Rev Psychiatr Neurosci 2006;31:122-31.
13. Guaiana G, Barbui C, Hotopf M.Amitriptyline for depression. Cochrane Database of Systematic Reviews 2007, Issue 2. Art. No.: CD004186. DOI: 10.1002/14651858.CD004186.pub2
14. Nutt D,Sharpe M. Uncritical positive regard? Issues in the efficacy and safety of psychotherapy. J Psychopharm 2008;22:3-6.
15. Artigas F, Nutt D, Shelton R. Mechanism of Action of Antidepressants. Psychopharm Bull 2002;36:(suppl 2):123-31.
16. Stahl S.Novel mechanism of antidepressant action: norepinephrine and dopamine disinhibition plus melatonergic agonism. Int J Neuropsychopharm 2007;10:575-8.
17. Schatzberg A, Blier P, Delgada P et al. Antidepressant Discontinuation syndrome: Consensus panel recommendations for clinical management and additional research. J Clin Psychiatry 2006;67(suppl 4):27-30.
18. Taylor D, Carol P, Kerwin R.The Maudsley Prescribing Guidelines 9th Edition.Informa HealthCare, London 2007.
19. Bazire S. Psychotropic Drug Directory 2007. HealthComm, Aberdeen 2007.
20. Baxter K. Stockley's Drug Interactions, 8th edn. London: Pharmaceutical Press, 2008.
21. Rush J, Trivedi M, Wisniewski S, et al. Bupropion-SR, Sertraline or venlaxaxine after failure of SSRIs for depression. NEJM 2006;354:1231-42.
22. Nierenberg M, Fava M,Trivedi M, et al. A comparison of Lithium and T3 augmentation following two failed medication treatments for depression:A STAR*D Report.Am J Psychiatry 2006;163:1519-30.
23. Papakostas GI,Shelton RC, Smith J, et al. Augmentation of antidepressants with atypical antipsychotic medication for treatment resistant-resistant major depressive disorders: a meta-analysis. J Clin Psychiatry 2007b;68:826-31.
24. Rojo JE, Ros S,Aguera L, et al. Combined antidepressants: clinical experience. Acta Psychiatrica Scand 2005;112:25-31.
25. McGrath P, Stewart J, Fava M, et al. Tranylcypromine versus venlafaxine plus mirtazapine following three failed antidepressant medication trials for depression:A STAR*D Report. Am J Psychiatry 2006;163:1531-41.
26. Abajo F, Garcia-Rodriguez L. Risk of Upper Gastrointestinal tract bleeding associated with selective serotonin reuptake inhibitors and venlafaxine therapy.Arch Gen Psychiatry 2008;65:795-803.
27. Boyer EW, Shannon M. Current concepts. The Serotonin Syndrome. NEJM 2005;352:1112-20.
28. Taylor D, Stewart S, Connolly A.Antidepressant withdrawal symptoms - Telephone calls to a national medication helpline. J Affect Disord 2006;95:129-33.
29. National Institute for Health and Clinical Excellence. Depression in children and young people. Clinical guideline 28.www.nice.org.uk. 2005.
30. Medicines and healthcare products regulatory agency. SSRIs. Findings of the Committee on Safety of Medicines.www.mhra.gov.uk 2004
31. Wheeler BW, Gunnell D, Metcalfe C, et al. The population impact on incidence of suicide and non-fatal self harm of regulatory action against the use of selective serotonin reuptake inhibitors in under 18s in the United Kingdom: ecological study. BMJ 2008;336(7643):542-5.
32. Gibbons RD, Brown CH, Hur K, et al. Early evidence on the effects of regulators' suicidality warnings on SSRI prescriptions and suicide in children and adolescents.Am J Psychiatry 2007;164:1356-63.
33. National Institute for Health and Clinical Excellence.Antenatal and postnatal mental health. Clinical Guideline 45.www.nice.org.uk. 2007.
34. Stahl S, Grady M. Differences in Mechanism of Action between current and future antidepressants. J Clin Psychiatry 2003;64(suppl 13):13-7.